急性冠脉综合征后脂蛋白(a)浓度与心血管事件风险:三种检测方法的比较
在ODYSSEY OUTCOMES试验的11 970例近期急性冠脉综合征患者中,比较了三种脂蛋白(a)检测方法(免疫比浊质量法、免疫比浊摩尔法、质谱法)的预后和预测价值。三种方法测得的脂蛋白(a)与主要不良心血管事件(MACE)风险的关系几乎相同,且均能预测阿利西尤单抗降低MACE的疗效。
要点
- 三种脂蛋白(a)检测方法在预测MACE风险方面表现相似。
- 阿利西尤单抗的相对风险降低在低脂蛋白(a)百分位时可能较小。
- 阿利西尤单抗的绝对风险降低随脂蛋白(a)水平升高而增加。
核心结论
- 在近期急性冠脉综合征患者中,三种脂蛋白(a)检测方法对安慰剂组MACE的预后价值相似。
- 三种检测方法对阿利西尤单抗降低MACE的预测价值在队列水平上相似。
研究设计与样本
- ODYSSEY OUTCOMES试验的事后分析,纳入11 970例近期急性冠脉综合征患者。
- 比较三种脂蛋白(a)检测方法:Siemens N-latex免疫比浊法(质量法,mg/dL)、Roche Tina-Quant免疫比浊法(摩尔法,nmol/L)和基于质谱的非商业检测(MS,nmol/L)。
- 将脂蛋白(a)值转换为百分位数进行建模比较,使用自然立方样条评估连续关系,并按各检测方法定义的基线脂蛋白(a)四分位数确定事件率。
主要发现
- 基线脂蛋白(a)中位数(Q1,Q3):IA-mass为21.8(6.9,60.0)mg/dL,IA-molar为45.0(13.2,153.8)nmol/L,MS为42.2(14.3,143.1)nmol/L。
- IA-molar与MS相关性最强(r=0.990),IA-mass与MS相关性稍弱(r=0.967),IA-mass与IA-molar相关性为r=0.972。
- 安慰剂组中脂蛋白(a)与MACE风险的关系在各检测方法间几乎相同,各百分位估计累积发生率差异≤0.4%,且在调整低密度脂蛋白胆固醇后均具有增量预后价值(所有样条P≤0.0003)。
- 阿利西尤单抗的预测治疗效果在各检测方法间也几乎相同,各百分位估计治疗风险比差异≤0.07,且三种检测均显示较低百分位时阿利西尤单抗的相对风险降低可能较小。
- 阿利西尤单抗的绝对风险降低随各检测方法测得的脂蛋白(a)升高而增加,四分位数间呈显著线性趋势。
临床怎么用
- 临床可选择任一上述脂蛋白(a)检测方法评估急性冠脉综合征后患者的MACE风险。
- 脂蛋白(a)水平较高的患者可能从阿利西尤单抗治疗中获得更大的绝对风险降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lipoprotein(a) is a risk factor for cardiovascular events and modifies the benefit of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Lipoprotein(a) concentration can be measured with immunoassays reporting mass or molar concentration or a reference measurement system using mass spectrometry. Whether the relationships between lipoprotein(a) concentrations and cardiovascular events in a high-risk cohort differ across lipoprotein(a) methods is unknown. We compared the prognostic and predictive value of these types of lipoprotein(a) tests for major adverse cardiovascular events (MACE). METHODS: The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) compared the PCSK9 inhibitor alirocumab with placebo in patients with recent acute coronary syndrome. We compared risk of a MACE in the placebo group and MACE risk reduction with alirocumab according to baseline lipoprotein(a) concentration measured by Siemens N-latex nephelometric immunoassay (IA-mass; mg/dL), Roche Tina-Quant turbidimetric immunoassay (IA-molar; nmol/L), and a noncommercial mass spectrometry-based test (MS; nmol/L). Lipoprotein(a) values were transformed into percentiles for comparative modeling. Natural cubic splines estimated continuous relationships between baseline lipoprotein(a) and outcomes in each treatment group. Event rates were also determined across baseline lipoprotein(a) quartiles defined by each assay. RESULTS: Among 11 970 trial participants with results from all 3 tests, baseline median (Q1, Q3) lipoprotein(a) concentrations were 21.8 (6.9, 60.0) mg/dL, 45.0 (13.2, 153.8) nmol/L, and 42.2 (14.3, 143.1) nmol/L for IA-mass, IA-molar, and MS, respectively. The strongest correlation was between IA-molar and MS (r=0.990), with nominally weaker correlations between IA-mass and MS (r=0.967) and IA-mass and IA-molar (r=0.972). Relationships of lipoprotein(a) with MACE risk in the placebo group were nearly identical with each test, with estimated cumulative incidences differing by ≤0.4% across lipoprotein(a) percentiles, and all were incrementally prognostic after accounting for low-density lipoprotein cholesterol levels (all spline P≤0.0003). Predicted alirocumab treatment effects were also nearly identical for each of the 3 tests, with estimated treatment hazard ratios differing by ≤0.07 between tests across percentiles and nominally less relative risk reduction by alirocumab at lower percentiles for all 3 tests. Absolute risk reduction with alirocumab increased with increasing lipoprotein(a) measured by each test, with significant linear trends across quartiles. CONCLUSIONS: In patients with recent acute coronary syndrome, 3 lipoprotein(a) tests were similarly prognostic for MACE in the placebo group and predictive of MACE reductions with alirocumab at the cohort level. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01663402.
引用
- Szarek M, Reijnders E, Jukema JW, et al. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests. Circulation. 2023. PMID: 37632469. doi:10.1161/CIRCULATIONAHA.123.066398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。